Trevi Therapeutics logo

Trevi Therapeutics Share Price (NASDAQ: TRVI)

Market is closed - opens 7 PM IST, 04 Aug 2025

$7.32

-0.09

(-1.21%)

Last updated on 02 Aug 2025, 01:29 AM IST

Check the interactive Trevi Therapeutics Stock chart to analyse performance

Trevi Therapeutics stock performance

as on 02 Aug 2025, 01:29 AM IST

  • Today's Low: $7.26
    Today's High: $7.49

    Day's Volatility :3.01%

  • 52 Weeks Low: $2.36
    52 Weeks High: $8.11

    52 Weeks Volatility :70.9%

Trevi Therapeutics Stock Returns

PeriodTrevi Therapeutics IncIndex (Russel 2000)
3 Months
6.16%
0.0%
6 Months
73.58%
0.0%
1 Year
154.78%
0.0%
3 Years
210.38%
-6.0%

Trevi Therapeutics Inc Key Stats

Check Trevi Therapeutics key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close
$7.41
Open
$7.43
Today's High
$7.485
Today's Low
$7.26
Market Capitalization
$903.4M
Today's Volume
$1.6M
52 Week High
$8.11
52 Week Low
$2.36
Revenue TTM
$0.0
EBITDA
$-50.9M
Earnings Per Share (EPS)
$-0.45
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-55.12%

Stock Returns calculator for Trevi Therapeutics Stock including INR - Dollar returns

The Trevi Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Trevi Therapeutics investment value today

Current value as on today

₹2,58,580

Returns

₹1,58,580

(+158.58%)

Returns from Trevi Therapeutics Stock

₹1,54,167 (+154.17%)

Dollar Returns*

₹4,413 (+4.41%)

Indian investors sentiment towards Trevi Therapeutics Stock

50%

Period: Jul 2, 2025 to Aug 1, 2025. Change in 30 Days versus previous period

Search interest for Trevi Therapeutics Stock from India on INDmoney has increased by 50% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Trevi Therapeutics Inc

  • Name

    Holdings %

  • NEA Management Company, LLC

    9.34%

  • BlackRock Inc

    4.36%

  • Rubric Capital Management LP

    3.73%

  • Vanguard Group Inc

    3.15%

  • Vivo Capital, LLC

    2.86%

  • MPM Oncology Impact Management LP

    2.82%

Analyst Recommendation on Trevi Therapeutics Stock

Rating
Trend

Buy

    91%Buy

    8%Hold

    0%Sell

Based on 12 Wall street analysts offering stock ratings for Trevi Therapeutics(by analysts ranked 0 to 5 stars)

Trevi Therapeutics Share Price Target

What analysts predicted

Upside of 189.92%

Target:

$21.22

Current:

$7.32

Trevi Therapeutics share price target is $21.22, a slight Upside of 189.92% compared to current price of $7.32 as per analysts' prediction.

Trevi Therapeutics Stock Insights

  • Price Movement

    In the last 1 month, TRVI stock has moved up by 23.8%

Trevi Therapeutics Technicals Summary

Sell

Neutral

Buy

Trevi Therapeutics is currently in a neutral trading position according to technical analysis indicators.

Trevi Therapeutics Inc Vs Peers

Returns
Ratio's
Overview
Company Name1 Month6 Month1 Year3 Years5 Years
Trevi Therapeutics Inc logo
23.11%
73.58%
154.78%
210.38%
210.38%
Regeneron Pharmaceuticals, Inc. logo
-0.36%
-16.51%
-48.55%
-8.54%
-13.7%
Beone Medicines Ltd logo
22.47%
33.89%
83.22%
76.22%
34.92%
Vertex Pharmaceuticals Incorporated logo
-0.64%
-1.72%
-6.51%
68.08%
65.38%
Alnylam Pharmaceuticals, Inc. logo
18.03%
46.25%
47.6%
89.4%
163.65%

About Trevi Therapeutics Inc

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF; phase 2 clinical trial in patients with pruritus; and phase 2b/3 clinical trial in patients with prurigo nodularis. Trevi Therapeutics, Inc. has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Organization
Trevi Therapeutics
Employees
31
CEO
Ms. Jennifer L. Good
Industry
Pharmaceuticals: Major

Key Management of Trevi Therapeutics Inc

NameTitle
Ms. Jennifer L. Good
Co-Founder, CEO, President & Director
Ms. Lisa Delfini
Chief Financial Officer
Dr. James V. Cassella Ph.D.
Chief Development Officer
Dr. Thomas R. Sciascia M.D.
Co-Founder & Chief Scientific Officer
Mr. Christopher Galletta
Controller & Chief Accounting Officer
Katie McManus
Communications Manager
Mr. Farrell Simon Pharm.D.
Chief Commercial Officer
Ms. Katherine Takaki Ph.D.
Senior VP of Global Regulatory Affairs

Important FAQs about investing in TRVI Stock from India :

How to invest in Trevi Therapeutics Stock (TRVI) from India?

It is very easy for Indian residents to invest directly in Trevi Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Trevi Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Trevi Therapeutics or TRVI on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Trevi Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Trevi Therapeutics shares which would translate to 0.119 fractional shares of Trevi Therapeutics as of today. Learn more about fractional investing.

Can Indians buy Trevi Therapeutics shares?

Yes, Indians can invest in the Trevi Therapeutics (TRVI) from India.

With INDmoney, you can buy Trevi Therapeutics at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Trevi Therapeutics at zero transaction cost.

How can I buy Trevi Therapeutics shares from India?

It is very easy to buy Trevi Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Trevi Therapeutics (TRVI) be purchased?

Yes, you can buy fractional shares of Trevi Therapeutics with INDmoney app.

What are the documents required to start investing in Trevi Therapeutics stocks?

To start investing in Trevi Therapeutics, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What is Trevi Therapeutics share price today?

Trevi Therapeutics share price today stands at $7.32, Open: $7.43 ; Previous Close: $7.41 ; High: $7.49 ; Low: $7.26 ; 52 Week High: $8.11 ; 52 Week Low: $2.36.

The stock opens at $7.43, after a closing price of $7.41. The stock reached a daily high of $7.49 and a low of $7.26, with a 52-week high of $8.11 and a 52-week low of $2.36.

What are today’s High and Low prices of Trevi Therapeutics Stock (TRVI)?

Today’s highest price of Trevi Therapeutics (TRVI) is $7.49.

Today’s lowest price of Trevi Therapeutics (TRVI) is $7.26.

What is the 52 Week High and Low Range of Trevi Therapeutics Stock (TRVI)?

  • 52 Week High

    $8.11

  • 52 Week Low

    $2.36

What are the historical returns of Trevi Therapeutics (TRVI)?

  • 1 Month Returns

    23.11%

  • 3 Months Returns

    73.58%

  • 1 Year Returns

    154.78%

  • 5 Years Returns

    210.38%

What is today's market capitalisation of Trevi Therapeutics?

Today's market capitalisation of Trevi Therapeutics TRVI is 903.4M

Who is the Chief Executive Officer (CEO) of Trevi Therapeutics ?

Ms. Jennifer L. Good is the current Chief Executive Officer (CEO) of Trevi Therapeutics.